News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
145,500 Results
Type
Article (10406)
Company Profile (49)
Press Release (135045)
Multimedia
Podcasts (19)
Webinars (4)
Section
Business (39638)
Career Advice (343)
Deals (18068)
Drug Delivery (22)
Drug Development (13057)
Employer Resources (26)
FDA (3306)
Job Trends (3984)
News (74788)
Policy (6480)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (2)
Academia (517)
Accelerated approval (7)
Adcomms (4)
Allergies (36)
Alliances (10188)
ALS (42)
Alzheimer's disease (293)
Antibody-drug conjugate (ADC) (137)
Approvals (3459)
Artificial intelligence (227)
Autoimmune disease (70)
Automation (13)
Bankruptcy (95)
Best Places to Work (3140)
BIOSECURE Act (3)
Biosimilars (31)
Biotechnology (36)
Bladder cancer (24)
Brain cancer (25)
Breast cancer (182)
Cancer (1293)
Cardiovascular disease (110)
Career advice (300)
Career pathing (8)
CAR-T (75)
CDC (9)
Cell therapy (199)
Cervical cancer (14)
Clinical research (11675)
Collaboration (569)
Company closure (1)
Compensation (75)
Complete response letters (16)
COVID-19 (503)
CRISPR (20)
C-suite (186)
Cystic fibrosis (24)
Data (1673)
Depression (39)
Dermatology (17)
Diabetes (140)
Diagnostics (1608)
Digital health (19)
Diversity (3)
Diversity, equity & inclusion (10)
Drug discovery (93)
Drug pricing (28)
Drug shortages (4)
Duchenne muscular dystrophy (38)
Earnings (17813)
Editorial (9)
Employer branding (3)
Employer resources (25)
Events (13093)
Executive appointments (215)
FDA (4251)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (9)
Frontotemporal dementia (9)
Funding (401)
Gene editing (46)
Generative AI (15)
Gene therapy (157)
GLP-1 (311)
Government (778)
Grass and pollen (1)
Guidances (191)
Healthcare (3765)
HIV (30)
Huntington's disease (6)
IgA nephropathy (27)
Immunology and inflammation (70)
Immuno-oncology (20)
Indications (40)
Infectious disease (581)
Inflammatory bowel disease (53)
Inflation Reduction Act (3)
Influenza (35)
Intellectual property (89)
Interviews (59)
IPO (3796)
IRA (8)
Job creations (963)
Job search strategy (244)
JPM (17)
Kidney cancer (1)
Labor market (14)
Layoffs (162)
Leadership (5)
Legal (1747)
Liver cancer (23)
Longevity (5)
Lung cancer (209)
Lymphoma (117)
Machine learning (16)
Management (7)
Manufacturing (270)
MASH (49)
Medical device (3214)
Medtech (3231)
Mergers & acquisitions (15092)
Metabolic disorders (384)
mRNA (43)
Multiple sclerosis (46)
NASH (2)
Neurodegenerative disease (93)
Neuropsychiatric disorders (29)
Neuroscience (623)
NextGen: Class of 2026 (1507)
Non-profit (784)
Now hiring (2)
Obesity (184)
Opinion (81)
Ovarian cancer (26)
Pain (42)
Pancreatic cancer (39)
Parkinson's disease (67)
Partnered (8)
Patents (152)
Patient recruitment (111)
Peanut (9)
People (10786)
Pharmaceutical (14)
Pharmacy benefit managers (5)
Phase 1 (3149)
Phase 2 (4913)
Phase 3 (4554)
Pipeline (2127)
Policy (40)
Postmarket research (483)
Preclinical (1400)
Press Release (6)
Prostate cancer (58)
Psychedelics (10)
Radiopharmaceuticals (80)
Rare diseases (287)
Real estate (1152)
Recruiting (9)
Regulatory (5160)
Reports (21)
Research institute (483)
Resumes & cover letters (60)
Rett syndrome (26)
RNA editing (2)
RSV (16)
Schizophrenia (57)
Series A (87)
Series B (43)
Service/supplier (2)
Sickle cell disease (22)
Special edition (7)
Spinal muscular atrophy (39)
Sponsored (12)
Startups (1014)
State (1)
Stomach cancer (2)
Supply chain (27)
Tariffs (14)
The Weekly (19)
Vaccines (230)
Venture capital (28)
Weight loss (125)
Women's health (25)
Worklife (2)
Date
Today (9)
Last 7 days (166)
Last 30 days (715)
Last 365 days (7437)
2026 (1982)
2025 (7745)
2024 (8029)
2023 (8457)
2022 (12566)
2021 (12378)
2020 (11583)
2019 (9771)
2018 (7913)
2017 (7127)
2016 (6342)
2015 (7574)
2014 (5307)
2013 (4272)
2012 (4403)
2011 (4696)
2010 (4350)
Location
Africa (175)
Alabama (28)
Alaska (1)
Arizona (62)
Arkansas (3)
Asia (9331)
Australia (1244)
California (2363)
Canada (800)
China (329)
Colorado (107)
Connecticut (123)
Delaware (91)
Europe (21224)
Florida (466)
Georgia (79)
Hawaii (1)
Idaho (15)
Illinois (219)
India (20)
Indiana (222)
Iowa (3)
Japan (160)
Kansas (12)
Kentucky (13)
Louisiana (16)
Maine (10)
Maryland (262)
Massachusetts (1706)
Michigan (73)
Minnesota (92)
Missouri (34)
Montana (5)
Nebraska (2)
Nevada (31)
New Hampshire (19)
New Jersey (975)
New Mexico (6)
New York (756)
North Carolina (437)
North Dakota (3)
Northern California (1200)
Ohio (90)
Oklahoma (2)
Oregon (4)
Pennsylvania (587)
Puerto Rico (7)
Rhode Island (10)
South America (282)
South Carolina (23)
Southern California (874)
Tennessee (107)
Texas (310)
United States (9416)
Utah (74)
Vermont (1)
Virginia (82)
Washington D.C. (20)
Washington State (207)
West Virginia (2)
Wisconsin (40)
Wyoming (1)
145,500 Results for "fianium acquired by nkt photonics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
GE HealthCare’s Photonova Spectra photon-counting CT receives FDA clearance
March 23, 2026
·
8 min read
Press Releases
Sakura Finetek Global and Hamamatsu Photonics K.K. Global Alliance Press Release
March 20, 2026
·
3 min read
Press Releases
Two Leaders in Pathology Innovation: Sakura Finetek and Hamamatsu Photonics K.K. Announce Global Alliance
March 20, 2026
·
3 min read
Press Releases
NiKang Therapeutics Presents Discovery of NKT5097, a First-in-Class, Highly Potent and Selective, Orally Bioavailable CDK2/4 Dual Degrader for Cancer Therapy at SABCS 2025
December 12, 2025
·
3 min read
Press Releases
NiKang Therapeutics® Completes Dosing of the First Cohort in a Phase 1 Study of NKT5097, a First-in-Class, Highly Potent and Selective, Orally Bioavailable CDK2/4 Dual Degrader
September 9, 2025
·
3 min read
Press Releases
SV Health Investors Acquires EpiVax
April 3, 2026
·
3 min read
Press Releases
Otsuka Pharmaceutical to Acquire Transcend Therapeutics
March 27, 2026
·
8 min read
BioCapital
NiKang Therapeutics Presents the Discovery and Unique Mechanism of Action of a Selective CDK2 Inhibitor NKT3447 at AACR Annual Meeting 2024
NiKang Therapeutics Inc. announced today the unveiling of NKT3447 at the American Association for Cancer Research (AACR) Annual Meeting 2024. NKT3447 is an orally bioavailable small molecule CDK2 inhibitor that exhibits high selectivity against CDK1 and other CDK.
April 5, 2024
·
3 min read
Press Releases
Nxera Pharma’s Partner Centessa Pharmaceuticals to be Acquired by Lilly
April 1, 2026
·
4 min read
Press Releases
Gilead Extends Tender Offer to Acquire Arcellx
April 2, 2026
·
8 min read
1 of 14,550
Next
